When the Right Formula Is the Wrong Product: hyaluronic acid (HA) Matrix Shot Case Study
At BF‑EssE, we’re known for finding solutions — but we’re also honest when something isn’t commercially viable. A client recently came to us with a complete formulation and documentation for a hyaluronic acid (HA) liquid shot, including collagen and additional actives.
Everything looked good on paper:
Clear tech documentation
Existing formulation
Lab-scale proof of concept
But after deep technical review and cost modeling, our conclusion was clear:
This formula was not scalable — at least not profitably. Here’s what happened.
Not Every Project Should Move Forward
The lab method for creating the HA shot involved:
Pre-weighing and dissolving each ingredient (including collagen and HA)
Controlled mixing in a jacketed reactor
Building a protective matrix for HA inside the liquid phase
Precision cooling before filling
All of this took 8+ hours of hands-on process time for just a small lab batch.
A Lab-Perfect Process… That Took 12 Hours
A Lab-Perfect Process…
The lab method for creating the HA shot involved:
Pre-weighing and dissolving
each ingredient (including collagen and HA)
Controlled mixing
in a jacketed reactor
Building a protective matrix
for HA inside the liquid phase
Precision cooling
before filling
All of this took 8+ hours of hands-on process time for just a small lab batch.
What Is a Matrix in HA Shot Formulation?
To keep hyaluronic acid stable in a liquid solution, especially alongside ingredients like collagen or amino acids, a protective matrix must be formed. This matrix:
Controls ionic interactions
and pH drift
Physically stabilizes HA chains
in solution
Prevents
early hydrolysis or microbial growth
Requires
preservatives, buffers, viscosity modifiers, and chelators
In practice, you're engineering a chemical cage inside a beverage. This isn’t just mixing powders in water — it’s pharma-level formulation. Without this matrix, HA degrades rapidly, and the product fails before it reaches the shelf.
(01)
We often talk about problem-solving in R&D — but sometimes saying no is the most professional decision. This wasn’t a failure. It was a well-reasoned stop.
(02)
The formulation may still be viable for luxury-tier brands or clinical trials — but not for high-volume commercial shots at marketable price points
Final Outcome:
Letting Go Is Also R&D
(04)
After an open discussion, both sides agreed: while technically feasible, the product wasn’t commercially viable at scale. It was better to stop now than to move forward into an unprofitable outcome.
(03)
“We work to deliver quality — not shortcuts. And this level of complexity comes with real cost.”
(02)
We understood the surprise — but this was no ordinary product. Our response was clear and respectful: “This isn’t just a flavored liquid. You’re asking us to develop a stabilized, multi-phase biochemical matrix — one that requires precision, equipment, and time.”
(01)
When we presented the full technical breakdown and cost forecast, the client was taken aback: “I didn’t expect it to be that expensive. It’s just a shot.”
Client Reaction:
Expectations vs. Reality
(02)
Every step added labor, equipment, and time cost.
(01)
After sitting down with our technical team and the client, we mapped out what it would take to scale this to production:
Heat-controlled jacketed tanks at multiple stages
Ingredient staging, weighing, and dissolving across three sub-processes
Controlled temperature curves (hot → cool) while preventing air exposure
HA matrix formation as a timed, temperature-specific stage
Cold filling in sterile conditions
SCALING
Scaling This Would Be… a Nightmare
From Concept to Constraint: The Reality of Scaling Complex Formulations
Real R&D Is Also Real Business
Formulation isn’t just about science — it’s about process, scale, and price.
In this case, we did everything right:
Analyzed the process
Modeled the cost
Advised the client based on facts
And then we chose not to proceed.
Because real R&D isn’t just about launching products — it’s about launching the right ones.